The bioactive phospholipid lysophosphatidic acid (LPA) causes growth cone collapse and neurite retraction in neuronal cells. These changes are brought about by the action of a cell surface receptor coupled to specific G proteins that control morphology and motility through the action of a group of small GTPases, the Rho family of proteins. Many studies have focused on actin reorganization modulated by Rho-GTPases, but almost no information has been obtained concerning microtubular network reorganization after LPA-induced neurite retraction. In the present study, we demonstrate an increase in site-specific Alzheimer's disease-like Tau phosphorylation during LPA-induced neurite retraction in differentiated SY-SH5Y human neuroblastoma cells. The phosphorylation state of Tau was inferred from its immunoreactivity with antibodies that recognize phosphorylation-sensitive epitopes. The effects of specific kinase inhibitors indicate that this phosphorylation is mediated by glycogen synthase kinase-3 (GSK-3). In support of this idea, we observed an increase of GSK-3 activity upon growth cone collapse. Our results are consistent with the hypothesis that activation of GSK-3 occurs in the Rho pathway and may represent an important link between microtubules and microfilaments dynamics during neuritogenesis and in pathological situations such as Alzheimer's disease.
Growth cones may be viewed as a signal transduction devices. During development they integrate complex positive and negative extracellular signals and physically direct neurite outgrowth through the regulation of cytoskeletal dynamics. Two major components of the cytoskeleton are involved in growth cone extension: actin microfilaments (MFs) 1 and microtubules (MTs). In combination with molecular motors (kinesins, dyneins, and myosins), these mediate the processes of advance, cessation, turning, branching, etc. of neuronal extension. In opposing processes such as extension and retraction, MTs and MFs may be precisely coordinated. MFs appear to regulate the initial events of the growth cone tip and filopodia and lamellipodia progression, and in a second step MTs stabilize the extended neurite (1) .
Microtubules are essential for neurite formation and maintenance. These structures are composed of tubulin and a variety of minor proteins denoted by microtubule-associated proteins (MAPs). The level of MAPs and, more importantly, their phosphorylation level appear to modulate microtubule stability and dynamics (2) . In particular, Tau, one of the most abundant axonal MAPs, may play a key role in axonogenesis (3, 4) . Tau phosphorylation is developmentally regulated, being lower in adult than in fetal brain. Additionally, Tau hyperphosphorylation occurs in the aberrant structures known as paired helical filaments (PHFs) that appear in neuronal disorders such as Alzheimer's disease where these structures are a neuropathological hallmark (5) .
The intracellular mechanisms that regulate neurite extension such as activation of the neurotrophin/neurotrophin receptor/mitogen-activated protein kinase (MAP kinase) pathway (6) are better understood than those implicated in growth cone collapse and neurite retraction (7) . Different groups of molecules that induce neurite retraction have been described (7) (8) (9) . Many of them, such as thrombin or LPA, may play a significant role in neuronal development (10) . Several studies of neuronal cell lines have revealed that LPA and thrombin induce neurite retraction, through G protein-coupled receptors (11, 12) , and the modulation of the activity of the small GTP-binding protein, Rho. These GTPases regulate many cellular processes, such as actomyosin-based contraction, actin and tubulin cytoskeleton organization, and cell shape (13) and cell division in many non-neuronal cells (14) . Depending on the cell type studied and the parameters measured, LPA initiates a wide range of transduction signals, not necessarily all of which are linked. For instance, three different G proteins have been implicated in the initial steps. One of these (G␣ 12/13 ) is located upstream of Rho and Rho-activated kinases and at least partially controls cytoskeletal organization (15) . The second GTP-binding protein (G i ) appears to be upstream of another set of kinases, such as phosphatidylinositol 3Ј-kinase (PI3Ј-kinase) and members of the MAP kinase superfamily, that mediate trophic effects (7) . The third heterotrimeric G protein (G q ) has been linked to the activation of phospholipases, resulting in protein kinase C activation and increasing intracellular calcium concentration (11, 16) .
Many studies have focused on actin reorganization modulated by Rho family proteins, but almost no information is available regarding how the microtubular network is reorganized after LPA-induced retraction.
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ease-like Tau phosphorylation. The state of Tau phosphorylation was inferred from its immunoreactivity with antibodies that recognize phosphorylation-sensitive epitopes. Our results using specific kinase inhibitors strongly support the hypothesis that this phosphorylation is mediated by GSK-3 ␤. Furthermore, in cell extracts from LPA-treated cells we observed an increase of GSK-3 activity associated with the neurite retraction. Our results are consistent with the hypothesis that the activation of GSK-3 kinase occurs in the Rho pathway and thus may constitute an important link between MT and MF dynamics.
MATERIALS AND METHODS
Lysophosphatidic acid (1-oleyl-9-(cis)-2-lyso-sn-glycero-3 phosphate) (LPA) was purchased from Sigma, and 1.3 mM stock solution was made in HEPES-buffered saline, 1 mM CaCl 2, 1 mM MgCl 2 , and 1% bovine serum albumin. Dibutyryl-cyclic AMP (db-cAMP) (Sigma) was used at a final concentration of 1 mM. Genistein, LiCl, pertussis toxin (PTX), and okadaic acid, all from Sigma, were used at different concentrations as indicated below. Wortmannin, the p38 inhibitor SB203580, and the MAP kinase kinase inhibitor PD98059 were obtained from Research Biochemicals, Inc. Protease inhibitors (phenylmethylsulfonyl fluoride, aprotinin, leupeptin, and pepstatin) were purchased from Sigma.
Cell Culture and Analysis of Neurite Outgrowth after Drug Treatments-SH-SY5Y human neuroblastoma cells were routinely grown in Dulbecco's modified Eagle's medium with 10% heat-inactivated fetal calf serum containing glutamine (2 mM) and antibiotics (penicillin/ streptomycin). To obtain a neuronal-like phenotype, the medium was changed to Neurobasal supplemented with B-27 (NB-B27) containing db-cAMP (1 mM) in which cells were maintained for 48 -72 h. To initiate neurite retraction the medium was changed to fresh NB-B27 without db-cAMP for 4 h, and then LPA (10 M) was included. The effect was analyzed 15, 30, 60, and 120 min after the addition of LPA. Controls without LPA in which db-cAMP was maintained were followed simultaneously. To interfere with neurite retraction, the inhibitors PTX, genistein, db-cAMP, or wortmannin were added in combination with LPA treatment.
RT-PCR and Northern Blot Analysis of LPA Receptors-Total RNA was purified from SH-SY5Y human neuroblastoma; N2A, NIE-115, and NRK mouse neuroblastoma cells; NIH-3T3, a mouse fibroblast cell line; and from primary cultures of astrocytes (kindly supplied by Dr. Gema Alvarez) (17) .
For Northern blot analysis, RNA (5 g/lane) was electrophoresed in formaldehyde-agarose gels and blotted onto nylon membranes by a positive pressure system (Stratagene). The RNA was cross-linked to the nylon filter by UV (Strata-linker). The hybridization was performed with 32 P-labeled EDG-2 c-DNA, in a solution containing 7.5ϫ SSC, 50% formamide in phosphate buffer (50 mM, pH 7) with t-RNA and salmon sperm DNA as carriers. The filters were incubated in this solution with the DNA probes at 42°C. To remove 32 P-labeled probe, filters were washed successively with 2ϫ SSC, 0.1% SDS for 30 min and 0.1ϫ SSC, 0.5% SDS for 30 min and were then exposed.
For RT-PCR, RNA (5 g) of each cell line was reverse-transcribed with specific primers: EDG-2 primers, gtcaaccgccgcttccattt (forward) and ctgtagaggggtgccatgtt (reverse); these primers should produce a 351-bp specific product; and EDG-4 primers, caatctgctggtcatagcag (forward) and actactgttgtcagaactgg (reverse), which should produce a 590-bp-specific product (18) . One microliter of each reverse transcription reaction were used in the PCR reactions (35 cycles). The amplifications were performed basically with the following protocol: 35 cycles of 95°C for 1 min, 54°C for 1 min, and 65°C for 2 min. The PCR products were subjected to electrophoresis on a 1.2% agarose gel, transferred to nylon, and hybridized with the cDNA probe corresponding to EDG-2 (vzg-1).
Antibodies and Western Blot Analysis-Monoclonal antibody against ␤3 tubulin (1:1000) and acetyl-tubulin (1:300) were purchased from Sigma. Tau monoclonal antibodies PHF-1 (1:30) were kindly supplied by Dr. P. Davies (Albert Einstein Coll, Bronx, NY), and Tau-1 (1:1000) was a kind gift of Dr. L. Binder (MGC, Chicago, IL). Using the residue numbering of the 441-amino acid human Tau isoform (19) . The monoclonal antibody Tau-1 recognizes the protein when serines 195, 198, 199 , and 202 are dephosphorylated, and PHF-1 recognized the serines 396 and 404 when they are in the phosphorylated form. Additionally, F-actin was visualized with phalloidin-fluorescein (1:400).
Cell extracts were prepared from semi-confluent differentiated SH-SY5Y. Cells were washed with 1ϫ PBS and were then resuspended in a buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM sodium ortho-vanadate, 5 mM EDTA, and protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin and 10 g/ml pepstatin) and disrupted with a Polytron homogenizer. The soluble fraction was obtained by centrifugation at 13,000 ϫ g for 10 min at 4°C. Proteins (25-50 g total) were separated in SDS-polyacrylamide gels and electrotransferred to a nitrocellulose filter. Nitrocellulose sheets were blocked with 5% nonfat milk in PBS, 0.1% Tween 20 (PBS-T). The nitrocellulose was then incubated with primary antibodies overnight at 4°C. Filters were rinsed three times in PBS-T buffer and then incubated with the corresponding peroxidaseconjugated secondary antibody (diluted 1:5000, Promega) for 1 h at room temperature. Immunoreactivity was visualized using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
Densitometric analysis was performed on different Western blot lanes (three replicates) and the data processed with an imaging densitometer (GS-6470 model, Bio-Rad). Data were analyzed with Molecular Analyst software. The densitometric values were normalized with respect to the values obtained for a control antibody to correct for any variations in the amounts of total loaded protein.
Quantitative Analysis of GSK-3 Activity-GSK-3 assays were carried out essentially as described previously (18) . Cell extracts were prepared from neuroblastoma cells at different times after the initiation of the growth cone collapse, and from control cells. Cells were collected with a cell scraper and homogenized in a buffer of 20 mM HEPES, pH 7.4, containing 100 mM NaCl, 100 mM NaF, 1 mM sodium ortho-vanadate, 5 mM EDTA, 100 nM okadaic acid, with protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml leupeptin, and 10 g/ml pepstatin). The soluble fraction was obtained after centrifugation at 13,000 ϫ g for 15 min at 4°C.
Samples of 5 g of protein were incubated in a buffer containing 25 mM Tris, pH 7.5, 1 mM dithiothreitol, and 10 mM MgCl 2 with a specific glycogen synthase substrate peptide (20) at a final concentration of 0.75 mg/ml in the presence of [␥-
32 P]ATP. After 1 h, the reaction was stopped by boiling, and the activity was quantified by spotting aliquots on P81 phosphocellulose paper. The difference between the kinase activity in the presence or absence of 20 mM LiCl (21) was considered to be a measure of GSK-3 protein kinase activity.
Indirect Immunofluorescence-After treatments, cell cultures were fixed with phosphate-buffered saline (PBS) containing paraformaldehyde (4%) for 30 min. After several washes with PBS, the cells were pre-incubated in PBS, containing 0.1% Triton X-100 and 1% fetal calf serum, for 30 min. After a brief wash with PBS, they were incubated overnight at 4°C with primary antibodies, diluted in PBS, containing 1% fetal calf serum and 0.1% Triton X-100. Following incubation with the primary antibody, cultures were extensively washed and then incubated with the appropriate secondary antibody, conjugated either with fluorescein or Texas-red (Jackson Laboratories) for 45 min. After washing, they were immediately mounted with Fluoromount, examined, and photographed under a Labophot (Nikon) or Axiophot (Zeiss) microscope.
RESULTS

LPA Induces Neurite Retraction in Differentiated SH-SY5Y-Initially
, we characterized the neuronal-like phenotype of SH-SY5Y after db-cAMP treatment. The differentiated phenotype was obtained after addition of this cAMP analog (1 mM) in the serum-free NB-B27 culture medium. The neuron-like phenotype was quite apparent 12 h after incubation. Characterization of the cytoplasmic extensions in these differentiated cells indicated that they are MAP1B-positive and Tau-positive, which is indicative of axon-like processes (data not shown).
After db-cAMP treatment, differentiated cells were incubated in the presence of 10 M LPA, and cell morphology was analyzed at different times after addition. Before the LPA treatment more than 95% of the differentiated cells showed processes. Neurite retraction was time-dependent, and the extended process was almost completely reduced 1-2 h after LPA addition. At this time, 80 -90% of cells were rounded and showed no cytoplasmic extensions. The analysis of tubulin and the actin network during the neurite retraction process showed that the polymerized actin is promptly disorganized 15 min after LPA addition. At this time, the reorganization of microtubules was not so evident. However, 60 min after LPA addi-tion, tubulin was no longer present in the axon-like extension but had accumulated in the cell body (Fig. 1, B and C) , clearly correlating with the morphological retraction.
LPA Receptor Characterization in Differentiated SH-SY5Y-The addition of LPA to differentiated SH-SY5Y cells induced an neurite retraction in a concentration-dependent manner. The retraction is detectable at a concentration as low as 10 nM (data not shown), being maximal at 5-10 M (Fig. 1) .
To characterize the involvement of a specific receptor in this response to LPA, we analyzed the expression in SH-SY5Y of the prototypical members of the LPA G protein-coupled receptors, EDG-2/vzg-1 and EDG-4 (22) .
RT-PCR with specific primers for EDG-2 and EDG-4 were performed with different neuroblastoma cell lines, as well as with NIH-3T3 as an EDG-2-positive control (18) . The RT-PCR reaction showed the presence of similar products in SH-SY5Y and NIH-3T3, with the predictable size of 351 bp. However, the expected EDG-4 product of 590 bp was not detectable in SH-SY5Y but was detectable in NIE-115 cells ( Fig. 2A) .
To fully confirm the presence of EDG-2 in SH-SY5Y, the RT-PCR products were transferred to a nylon filter, and the blot was hybridized with the 32 P-labeled cDNA probe of EDG-2 (Fig. 2B) .
In the same way, the Northern blot analysis of RNA samples from SH-SY5Y and NRK neuroblastomas, from NIH-3T3 fibroblasts, and from primary astrocytes showed the presence of a 3.8-kilobase EDG-2 mRNA in all cells lines. However, the amount of the EDG-2 mRNA in SH-SY5Y appears to be 5-10 times lower than in 3T3 cells. (Fig. 2C) .
Tau Phosphorylation during LPA-Neurite Retraction-Biochemically, neurite retraction may be the opposite of neurite outgrowth. Also, one of the most important elements that mediates the stability of microtubules is the phosphorylation level of MAPs (23) . Taking these facts into account, we tested the phosphorylation level of Tau protein present in the differentiated SH-SY5Y and analyzed how it is modified during the process of neurite retraction. LPA-treated cells were obtained at different times during the retraction process. Cell extracts were analyzed by Western blot using antibodies that recognized specifically phosphorylated and nonphosphorylated Tau epitopes, as described previously (24) .
The LPA treatment results in a site-specific phosphorylation of Tau, as confirmed by the increase of PHF-1 immunoreactivity, which reached its highest level 60 min after LPA addition and then decreased (Fig. 3A) . This phosphorylation increase was evident when compared with the total amount of Tau or of tubulin (Fig. 3A) . The data from three independent experiments showed a 2-2.5-fold increase of PHF-1 immunoreactivity, 60 min after addition, when densitometric data was referred to the total amount of Tau or to the total amount of ␤ tubulin (Fig. 3B) .
The decrease of PHF-1 immunoreactivity without an appreciable decrease of Tau protein suggested the presence of a phosphatase activity. To confirm this hypothesis, we performed similar LPA-induced neurite retraction experiments in the presence of 400 nM okadaic acid. The addition of okadaic acid 60 min after LPA treatment not only blocked the decrease of PHF-1 immunoreactivity but even increased the phosphorylation level of Tau from 60 to 120 min (Fig. 3C) . The Western blot and the quantitative data from these blots showed that the phosphorylation level at 120 min is almost four times higher than the control level.
Influence of the Modification of LPA-Neurite Retraction Pathway on Tau Phosphorylation-Different transduction signaling pathways have been described as being initiated by LPA binding to its receptor(s). Three different G proteins, one of them PTX-sensitive, have been described (see the Introduction) as being coupled to the LPA receptor. We found that the addition of PTX (50 or 100 ng/ml) before or during the retraction process did not modify the collapse. The analysis of Tau protein phosphorylation, using the antibody PHF-1, showed no significant differences between treatment (PTX plus LPA) or control (LPA alone) (Fig. 3, left) , except that Tau phosphorylation did not peak in the presence of PTX 60 min after LPA treatment but continued to increase after 120 min (Fig. 4) . The quantitative data from different Western blots for PHF-1 immunoreactivity with respect to the amount of tubulin indicated a 3-fold increase over the treatment with PTX alone.
Additionally, many protein kinases, such as protein kinase A, PI3Ј-kinase, or tyrosine kinase(s), have been implicated in the regulation of LPA-activated pathway(s) (7) . We analyzed the LPA-induced neurite retraction and the level of LPA-mediated Tau phosphorylation after modifying these kinases, adding db-cAMP to activate protein kinase A, wortmannin to inhibit PI3Ј-kinase, or genistein to inhibit cytoplasmic tyrosine kinases.
The addition of db-cAMP (2 mM) or the tyrosine kinase inhibitor genistein (100 M) 30 min before LPA addition is known (for review see Ref. 7) to prevent growth cone collapse and neurite retraction by maintaining the neuron-like phenotype (data not shown). Our biochemical data confirm that the LPAinduced increment in the phosphorylation level of Tau protein, using the antibody PHF-1, was blocked by db-cAMP (data not shown) or genistein (Fig. 4, right) treatments. Thus, the addition of these compounds also correlated with the inhibition of neurite retraction. On the contrary, the addition of wortmannin (100 nM) neither altered the collapse nor modified the LPA-induced phosphorylation pattern produced by PHF-1 antibody (Fig. 4, center) .
Implication of GSK-3 in Tau Phosphorylation
Induced by LPA-The reaction of Tau protein with PHF-1 antibody is increased in Alzheimer's disease pathology, and three main kinases (GSK-3, MAP kinases, and stress kinases) have been implicated in its phosphorylation (25) . We determined the possible role of these kinases in Tau phosphorylation during neurite retraction. To establish whether one of these kinases is responsible for Tau phosphorylation by LPA, we used three compounds that specifically inhibit the mentioned kinases. LiCl for GSK-3 (21), the inhibitor SB203580 for stress kinase p38, and the inhibitor of MAP kinase kinase, PD98059.
Treatment of differentiated cells with LiCl (20 mM) 2 h before LPA addition partially prevented neurite collapse (data not shown) and almost completely prevented the reaction with PHF-1 antibody (Fig. 5A) . That this happens because of dephosphorylation of Tau is corroborated by the increase of Tau-1 immunoreactivity (Fig. 5B) . Kinase inhibition by LiCl was specific, since addition of an identical concentration of NaCl as an osmotic control had no effect on the phosphorylation state of Tau (data not shown). Furthermore, the effect appears to be specific for GSK-3 because the inhibition of stress kinase p38 with SB203580 (25 M), or that of MAP kinase kinase with PD98059 (100 M), showed no differences from that observed with LPA treatment in the absence of these drugs, except that after MAP kinase inhibition, Tau phosphorylation did not peak at 60 min after treatment but continued to increase after 120 min (Fig. 5A) .
Increase of GSK-3 Activity after LPA Treatment-The fact that Tau immunoreactivity increased with PHF-1 antibody after LPA treatment, in combination with the observed inhibition of this specific phosphorylation by LiCl, strongly suggests that GSK-3 activity is increased after LPA addition. To test this hypothesis directly, GSK-3 activity was measured in cell extracts obtained after LPA addition, using a specific peptide as a GSK-3 substrate.
Data from three experiments showed that the GSK-3 specific activity increased 6 -7-fold 30 min after LPA addition. This increase was maintained around 5-fold from 60 min to 120 min after addition (Fig. 6) . No differences were detected in the total amount of the GSK-3 protein, as indicated by the Western blot (Fig. 5) . 
DISCUSSION
The present study has focused on the analysis of how the microtubular network is reorganized after LPA-induced neurite retraction. We initially characterized the LPA receptor(s) that are present in SH.SY5Y neuroblastoma cells. From the prototypical EDG family proteins, two receptors have been specifically associated with LPA, EDG-2/vzg-1 and EDG-4 (22) . Our data from RT-PCR showed the presence of a fragment corresponding to EDG-2 receptor with its predicted size of 351 bp (18) . This fact was fully confirmed by the hybridization with the EDG-2 cDNA and by Northern blot. On the other hand, EDG-4 was not detected in our cell line although it has been observed in other mouse neuroblastoma lines. Our data from Northern blot analysis showed the presence of the EDG-2 mRNA with the same size as that of control cells (NIH-3T3). From these results we conclude that at least the EDG-2 LPA receptor is expressed in SH-SY5Y cells. In addition, the presence of other LPA receptors, such as the PSP24-like members,
can not yet be discarded.
In our differentiated neuroblastoma cells, as in primary neurons, microtubule dynamics are largely determined by the polymerization capacity of tubulin modulated by the specific tubulin-binding capacity of each MAP. This tubulin-stabilizing capacity of MAPs in turn appears to be regulated by their phosphorylation level (2, 23) . To establish whether the phosphorylation level of MAPs plays a key role during the retraction process, we used differentiated SH-SY5Y neuroblastoma cells as a model system.
We studied Tau phosphorylation levels because it is the most abundant MAP in the mature axon, and it may play an essential role not only in neurite outgrowth but specifically in axon elongation (3, 4) . It has been demonstrated in vitro that Tau phosphorylation influences tubulin binding capacity and affects tubulin polymerization capacity and microtubule dynam- FIG. 6 . Quantitative analysis of the GSK-3 kinase activity. Cell extracts from SH-SY5Y control cells (0) and after 30, 60, and 120 min after LPA addition were used to quantify GSK-3 activity. We consider specific activity the percentage of radioactivity incorporated in the glycogen synthase peptide, which is inhibited by lithium chloride. Total GSK-3 protein was determined by densitometric analysis from Western blot. GSK-3 activity normalized with respect to total GSK-3 protein present in each cell extract was expressed as the mean of three different experiments. Data from control cells was considered 100 relative units. Error bars represent standard deviations, and * is statistically significant (p Ͻ 0.001). ics. During early developmental stages Tau is more heavily phosphorylated than in the adult brain, where a lower level of phosphorylation may favor axonal stability. This decrease of phosphorylation in the adult brain may be due to the downregulation of kinases and/or the up-regulation of phosphatases (3, 26 -29) .
In this study of SH-SY5Y differentiated neuroblastoma, we describe how Tau is more heavily phosphorylated during LPAinduced neurite retraction than in controls of untreated differentiated cells. Tau phosphorylation was inferred from its immunoreactivity with antibodies, denoted by PHF-1 and Tau-1, that recognize phosphorylation-sensitive epitopes.
The fact that the immunoreactivity visualized by PHF-1 antibody decreased from 60 to 120 min after LPA addition, without an appreciable decrease of the total Tau, suggested the presence of a phosphatase activity. To confirm this hypothesis we repeated the experiment in the presence of okadaic acid, a potent inhibitor of phosphatase 1 and 2A. In the presence of this compound, after the initial augmentation of PHF-1 immunoreactivity, phosphorylation was further increased until 120 min; the decrease detected from 60 to 120 min with LPA alone was not observed in the presence of okadaic acid. This result implies the presence of a phosphatase activity 2A and/or 1 during the LPA-induced neurite retraction.
Similar conclusions may be inferred from PTX treatment, which showed that in combination with LPA, the decrease of Tau phosphorylation was not detected. Indeed, it has been recently reported that PTX treatment correlated with the inhibition of a phosphatase 2A-like activity in neuroblastoma cells (30) . Further study will establish the specific contribution of each phosphatase in the dephosphorylation process associated with the LPA-induced neurite retraction.
Data from other studies of neuroblastoma cell lines (12, 16) as well as our own studies 2 have indicated that neurite retraction may be blocked by some compounds that modify the status of some kinases or phosphatases. In our SH-SY5Y neuroblastoma model, we differentiated the cells by adding db-cAMP. However, this compound, which may directly activate protein kinase A, cannot be present during the LPA-induced retraction. In agreement with previous reports, the addition of new dbcAMP before LPA treatment partially prevents neurite retraction (31) . Interestingly, Tau obtained from these db-cAMP plus LPA-treated cells showed no differences in its phosphorylation level with respect to control differentiated untreated cells.
The LPA receptor appears to be coupled to three different G proteins (G i , G␣ 12/13 , and G␣ q ). These may be distinguished because only one of them (G i ) is sensitive to PTX (7). The addition of PTX before LPA treatment still allows the Tau hyperphosphorylation induced during collapse. Similarly, the inhibition of PI 3Ј-kinase, which may be located downstream of the PTX-sensitive pathway, also favors the Tau phosphorylation pattern induced by LPA.
These results raise the possibility that the PTX-insensitive pathway, which includes Rho and different Rho-activated kinases downstream, may be responsible for Tau phosphorylation. The key control component of the LPA-Rho pathway appears to be one (or more) undefined tyrosine kinase(s) that may be inhibited by genistein (32) . Our results show that the addition of genistein 30 min before LPA simultaneously prevents growth cone collapse and Tau phosphorylation in its PHF1 epitope. However, the exact location of this tyrosine kinase (or group of kinases) in the Rho pathway is not clear (scheme in Fig. 7 ). Some authors consider that it may be located upstream of Rho and others, downstream (for review see Refs. 7 and 33). Our data strongly support the hypothesis that the serine-threonine kinase responsible for this Tau phosphorylation is located downstream of a tyrosine kinase. We also know that the antibody PHF1 recognizes Tau when serines 396 and 404 are phosphorylated (34) . The hyperphosphorylated Tau present in the PHFs of Alzheimer's disease brains are recognized by the PHF antibody, and this phosphorylation may precede the disruption of microtubule cytoskeleton and the formation of PHFs in Alzheimer's disease (35) (36) (37) . Among the initial group of Tau protein kinases, Tau protein kinase-1 (TPKI), which was characterized as glycogen synthase kinase 3, was found to be a kinase able to generate PHF-1 epitopes (for review see Refs. 24, 25, and 38) . Moreover, GSK-3 has been found to co-purify with PHF from Alzheimer's disease brains. All these data indicate that GSK-3 may be largely responsible for the phosphorylation of the epitope PHF-1.
In our study, using SH-SY5Y differentiated neuroblastoma, we describe how the reaction of Tau protein with PHF-1 antibody increases during LPA-induced neurite retraction. In this model, we used a specific inhibitor (LiCl) for GSK-3 (21) , and this compound achieved the complete inhibition of Tau LPAinduced phosphorylation. Control data showed that this effect was not due to an osmotic change, because NaCl at the same concentration had no effect, and that the inhibition of the stress kinase p38, considered a mediator of osmotic stress, did not reduce PHF-1 Tau phosphorylation. In addition, the inhibition of MAP kinase did not prevent the retraction nor the Tau hyperphosphorylation after LPA treatment. All of these data strongly support the hypothesis that GSK-3 activity increases after LPA collapse, as was confirmed by the direct measurement of GSK-3 activity from cell extracts.
The activity of GSK-3 is regulated by both serine and tyrosine phosphorylation. Phosphorylation of GSK-3 at Ser 9 correlates with inhibition of GSK-3 activity (39), whereas tyrosine phosphorylation correlates with an increase of kinase activity. Recently, using SH-SY5Y neuroblastoma cells, it was reported (40) that after insulin addition, transient Tau phosphorylation FIG. 7 . Schematic model of the GSK-3 regulation by the Rho pathway. The stimulation of the LPA receptor induces growth cone collapse and neurite retraction. The RhoA GTPase and Rho-kinase (ROK) may be the systems that control the actomyosin machinery, whereas an undefined genistein-inhibitable tyrosine kinase (TK) may control GSK-3 activity.
followed by a dephosphorylation occurred, and in parallel there was activation of GSK-3. This kinase activation was associated with an increase in GSK-3 tyrosine phosphorylation. In addition, these results showed that GSK-3 phosphorylation is associated with the presence of Fyn tyrosine kinase associated with GSK-3 tyrosine phosphorylated (40) . In our LPA-induced neurite retraction model, we detected an significant increase in the GSK-3 activity, and we speculate that a similar activation system exists. Further studies are required to define precisely how GSK-3 is activated during LPA-induced neurite retraction.
A similar activation system may be responsible for the Tau hyperphosphorylation in some pathological processes in which neurite integrity may be compromised. Alzheimer's disease, in which GSK-3 activation has been related to A␤ peptide toxicity (41) , is one such process. Recent data on the overexpression of the human amyloid precursor protein mutant in the mouse brain strongly support this hypothesis (42) .
Our results are consistent with the hypothesis that Tau is phosphorylated by the activation of GSK-3 during LPA-induced neurite retraction. The GSK-3 activation process appears to be linked with the PTX-insensitive pathway, in which an undefined cytoplasmic tyrosine kinase up or downstream of Rho is the key (scheme in Fig. 7 ). It is important to remember that almost all the regulatory pathways that are so far known to control GSK-3 activity directly (e.g. IGF-1 (43) or Wnt (44)) are based on the inhibition of GSK-3 kinase activity, whereas only a transient activation of GSK-3 has been reported after insulin addition (40) . Furthermore, the decrease of GSK-3 activity appears to be an important step in neuritogenesis (45) .
The present report is the first demonstration of a neuronal response mediated by a membrane receptor that is associated with a sustained activation of GSK-3. This response may represent a Rho pathway link between MT and MF dynamics during neurite retraction.
